Search Result

Pathways Recommended:	Autophagy

Results for "

Autophagy activator-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Atg8/LC3 (1) Autophagy (23) Mitophagy (6) Akt (1) AMPK (2) Androgen Receptor (2) Apoptosis (10) Ferroptosis (5) FLT3 (5) HIV (4) Isotope-Labeled Compounds (3) Necroptosis (1) Organoid (2) p38 MAPK (2) p62 (1) PARP (4) PKC (1) RABV (1) Raf (5) Reverse Transcriptase (3) RIP kinase (1) VEGFR (5)
By Research Areas:	Cancer (19) Infection (4) Inflammation/Immunology (2) Neurological Disease (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Autophagy AUTOTACs AUTACs Mitophagy Atg4 Atg8/LC3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10201S2

Sorafenib-13C,d3 1 Publications Verification	Raf VEGFR FLT3 Autophagy Apoptosis Ferroptosis	Cancer
Sorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].

HY-70002

Enzalutamide 155+ Cited Publications MDV3100	Androgen Receptor Autophagy	Cancer
Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist with an IC₅₀ of 36 nM in LNCaP prostate cells. Enzalutamide is an *autophagy* activator .

HY-135825

TFEB activator 1 4 Publications Verification	Autophagy	Neurological Disease
TFEB activator 1 is an orally effective, mTOR-independent activator of TFEB. TFEB activator 1 significantly promotes the nuclear translocation of Flag-TFEB with an EC₅₀ of 2167 nM. TFEB activator 1 enhances *autophagy* without inhibiting the mTOR pathway and has the potential for neurodegenerative diseases treatment .

HY-10162

Olaparib 215+ Cited Publications AZD2281; KU0059436	PARP Autophagy Mitophagy	Cancer
Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC₅₀s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an *autophagy* and mitophagy activator .

HY-100548

GSK621 3 Publications Verification	AMPK Autophagy Apoptosis	Cancer
GSK621 is a specific AMPK activator, with IC₅₀ values of 13-30 μM for AML cells. GSK621 induces *autophagy* and apoptosis. GSK621 induces eiF2α phosphorylation-a hallmark of UPR activation .

HY-10162S1

Olaparib-d8 AZD2281-d₈; KU0059436-d₈	PARP Autophagy Mitophagy	Cancer
Olaparib-d₈ is the deuterium labeled Olaparib (AZD2281). Olaparib is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4].

HY-170667

**Autophagy activator-1**	Autophagy Atg8/LC3 p62	Cancer
Autophagy activator-1 (Compound B2) is an *autophagy* activator .

HY-159894

**Autophagy-lysosome activator-1**	Autophagy	Cancer
Autophagy-lysosome activator-1 (Compound F1) is a *Autophagy-lysosome* activator. Autophagy-lysosome activator-1 effectively induces PD-L1 or VISTA degradation in tumor cells .

HY-168640

RIP3 activator 1	Autophagy Necroptosis RIP kinase	Cancer
RIP3 activator 1 (compound C8) is a potent RIP3 activator. RIP3 activator 1 inhibits cell growth. RIP3 activator 1 induces necroptosis through the RIP3/p62/Keap1 signaling pathway. RIP3 activator 1 increases the protein expression of p-MLKL. RIP3 activator 1 induces *autophagy. RIP3 activator 1* increases accumulation of LC3-II and p62 protein expression .

HY-70002R

Enzalutamide (Standard)	Androgen Receptor Autophagy	Cancer
Enzalutamide (Standard) is the analytical standard of Enzalutamide. This product is intended for research and analytical applications. Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist with an IC₅₀ of 36 nM in LNCaP prostate cells. Enzalutamide is an *autophagy* activator .

HY-14266

Dapivirine 2 Publications Verification TMC120; R147681	HIV Reverse Transcriptase Apoptosis Autophagy	Infection
Dapivirine (TMC120), the prototype of diarylpyrimidines (DAPY), is an orally active and nonnucleoside reverse transcriptase inhibitor (NRTI). Dapivirine (TMC120) binds directly to HIV-1 reverse transcriptase. Dapivirine (TMC120) regulates autophagy and induced Akt, Bad and SAPK/JNK activations .

HY-10162S3

Olaparib-d4-1 AZD2281-d₄-1; KU0059436-d₄-1	Isotope-Labeled Compounds PARP Autophagy Mitophagy	Cancer
Olaparib-d₄-1 is the deuterium labeled Olaparib. Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4].

HY-10162R

Olaparib (Standard)	PARP Autophagy Mitophagy	Cancer
Olaparib (Standard) is the analytical standard of Olaparib. This product is intended for research and analytical applications. Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC₅₀s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an *autophagy* and mitophagy activator .

HY-14266S

Dapivirine-d11 TMC120-d₁₁; R147681-d₁₁	Isotope-Labeled Compounds HIV Reverse Transcriptase Apoptosis Autophagy	Infection
Dapivirine-d₁₁ is the deuterium labeled Dapivirine. Dapivirine (TMC120), the prototype of diarylpyrimidines (DAPY), is an orally active and nonnucleoside reverse transcriptase inhibitor (NRTI). Dapivirine (TMC120) binds directly to HIV-1 reverse transcriptase. Dapivirine (TMC120) regulates autophagy and induced Akt, Bad and SAPK/JNK activations[1][2].

HY-10249

GSK-690693 30+ Cited Publications	Akt AMPK Autophagy	Cancer
GSK-690693 is an ATP-competitive pan-Akt inhibitor with IC₅₀s of 2 nM, 13 nM, 9 nM for Akt1, Akt2 and Akt3, respectively. GSK-690693 is also an AMPK inhibitor, affects Unc-51-like autophagy activating kinase 1 (ULK1) activity and robustly inhibits STING-dependent IRF3 activation .

HY-14266S1

Dapivirine-d4 TMC120-d₄; R147681-d₄	Isotope-Labeled Compounds Apoptosis Reverse Transcriptase Autophagy HIV	Infection
Dapivirine-d₄ (TMC120-d₄) is deuterium labeled Dapivirine. Dapivirine (TMC120), the prototype of diarylpyrimidines (DAPY), is an orally active and nonnucleoside reverse transcriptase inhibitor (NRTI). Dapivirine (TMC120) binds directly to HIV-1 reverse transcriptase. Dapivirine (TMC120) regulates autophagy and induced Akt, Bad and SAPK/JNK activations .

HY-10201A

Sorafenib Tosylate 190+ Cited Publications Bay 43-9006 Tosylate	Raf VEGFR FLT3 Autophagy Ferroptosis Apoptosis	Cancer
Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active Raf inhibitor with IC₅₀s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. SorafenibTosylate is a multikinase inhibitor with IC₅₀s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib Tosylate induces *autophagy* and apoptosis. Sorafenib Tosylate has anti-tumor activity. Sorafenib Tosylate is a ferroptosis activator .

HY-10201

Sorafenib 190+ Cited Publications Bay 43-9006	Raf VEGFR FLT3 Autophagy Apoptosis Ferroptosis	Cancer
Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC₅₀s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC₅₀s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces *autophagy* and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator .

HY-10201AR

Sorafenib (Tosylate) (Standard)	Raf VEGFR FLT3 Autophagy Ferroptosis Apoptosis	Cancer
Sorafenib (Tosylate) (Standard) is the analytical standard of Sorafenib (Tosylate). This product is intended for research and analytical applications. Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active Raf inhibitor with IC₅₀s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. SorafenibTosylate is a multikinase inhibitor with IC₅₀s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib Tosylate induces *autophagy* and apoptosis. Sorafenib Tosylate has anti-tumor activity. Sorafenib Tosylate is a ferroptosis activator .

HY-10201R

Sorafenib (Standard)	Raf VEGFR FLT3 Autophagy Apoptosis Ferroptosis	Cancer
Sorafenib (Standard) is the analytical standard of Sorafenib. This product is intended for research and analytical applications. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC₅₀s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC₅₀s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces *autophagy* and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator .

HY-10256

Adezmapimod Maximum Cited Publications 458 Publications Verification SB 203580; RWJ 64809	Organoid p38 MAPK Autophagy Mitophagy	Inflammation/Immunology Cancer
Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC₅₀s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC₅₀s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod does not disrupt JNK activity and is an *autophagy* and mitophagy activator .

HY-10256A

Adezmapimod hydrochloride Maximum Cited Publications 458 Publications Verification SB 203580 hydrochloride; RWJ 64809 hydrochloride	Organoid p38 MAPK Autophagy Mitophagy	Inflammation/Immunology Cancer
Adezmapimod (SB 203580; RWJ 64809) hydrochloride is a selective and ATP-competitive p38 MAPK inhibitor with IC₅₀s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod hydrochloride inhibits LCK, GSK3β and PKBα with IC₅₀s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod hydrochloride does not disrupt JNK activity and is an *autophagy* and mitophagy activator .

HY-18980

Rottlerin 5+ Cited Publications Mallotoxin; NSC 56346; NSC 94525	PKC Autophagy Apoptosis HIV RABV	Infection Cancer
Rottlerin, a natural product purified from Mallotus Philippinensis, is a specific PKC inhibitor, with IC₅₀ values for PKCδ of 3-6 μM, PKCα,β,γ of 30-42 μM, PKCε,η,ζ of 80-100 μM. Rottlerin acts as a direct mitochondrial uncoupler, and stimulates autophagy by targeting a signaling cascade upstream of mTORC1. Rottlerin induces apoptosis via caspase 3 activation . Rottlerin inhibits HIV-1 integration and Rabies virus (RABV) infection .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-18980

Rottlerin 5+ Cited Publications Mallotoxin; NSC 56346; NSC 94525	Structural Classification Chalcones Flavonoids Classification of Application Fields Source classification Phenols Polyphenols Euphorbiaceae Plants Disease Research Fields Mallotus philippensis Cancer	PKC Autophagy Apoptosis HIV RABV
Rottlerin, a natural product purified from Mallotus Philippinensis, is a specific PKC inhibitor, with IC₅₀ values for PKCδ of 3-6 μM, PKCα,β,γ of 30-42 μM, PKCε,η,ζ of 80-100 μM. Rottlerin acts as a direct mitochondrial uncoupler, and stimulates autophagy by targeting a signaling cascade upstream of mTORC1. Rottlerin induces apoptosis via caspase 3 activation . Rottlerin inhibits HIV-1 integration and Rabies virus (RABV) infection .

Cat. No.	Product Name	Chemical Structure

HY-10201S2

Sorafenib-13C,d3 1 Publications Verification
Sorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].

Sorafenib-13C,d3

1 Publications Verification

Sorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].